Pfizer Q2 Results Review - Subuded Growth, NCE Pipeline Commercialisation Is Awaited: Systematix

Systematix Research Report

Pfizer Ltd.’s Q2 FY25 revenue (Rs 5,886 million) was higher ~2.3% YoY and 4.6% QoQ. Revenue growth was lower than our expectations (8% YoY growth). We were expecting a strong contribution during the quarter from relaunch of Magnex Forte, which was the single the largest product in the antibiotic portfolio where supplies got disrupted last year.

We are not sure to what degree has Pfizer been able to restore market share for its relaunched antibiotic portfolio so far. Prior to supply disruption, the antibiotic portfolio contribution to revenue was close to 6% of revenue. Ebitda (Rs 1,893 million) and net earnings (Rs 1,584 million) were lower than our expectations by ~6%.

We retain our estimates on Pfizer and would expect the growth momentum to pick up in the H2 FY25.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.